Document Detail

Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients.
MedLine Citation:
PMID:  11273876     Owner:  NLM     Status:  MEDLINE    
The effectiveness of intravenous folinic acid or intravenous folic acid for the treatment of hyperhomocysteinemia of hemodialysis patients is unknown. In a randomized, controlled, double-blind trial, 66 hemodialysis patients were administered either 15 mg of folic acid or an equimolar amount (16.1 mg) of folinic acid intravenously three times weekly. Normalization of total homocysteine (tHcy) plasma levels after 4 weeks of treatment was achieved in 10 patients (30.3%) in the folic-acid group and 6 patients (18.2%; P: = 0.389) in the folinic-acid group (normalization at any time during the study period in 39.4% and 33.3% of the patients; P: = 0.798). The relative reduction in tHcy plasma levels at week 4 was 32.2% in the folic-acid group and 34.1% in the folinic-acid group. A high baseline tHcy plasma concentration (P: = 0.00001), methylenetetrahydrofolate reductase (MTHFR) 677TT/1298AA genotype (P: = 0.03540), and low red blood cell folate concentrations (P: = 0.02285) were associated with a better relative response to treatment. Normalization of tHcy plasma levels was dependent on a lower baseline tHcy level (P: = 0.01976), younger age (P: = 0.00896), and MTHFR 677TT/1298AA or 677CT/1298AC genotypes (P: = 0.00208 and P: = 0.02320, respectively). A 4-week course of intravenous folinic acid is not superior to intravenous folic acid in reducing elevated tHcy plasma levels in hemodialysis patients. The response to treatment is predicted by tHcy plasma level, red blood cell folate content, and MTHFR genotype.
A C Hauser; W Hagen; P H Rehak; H Buchmayer; M Födinger; M Papagiannopoulos; C Bieglmayer; R Apsner; E Köller; M Ignatescu; W H Hörl; G Sunder-Plassmann
Related Documents :
12146876 - Fate of resin acids in pulp mill secondary treatment systems.
3076436 - Methanopterin and methanogenic bacteria.
11588136 - The effect of folic acid deficiency and mthfr c677t polymorphism on chromosome damage i...
8111246 - Studies on cassia pollen grains of india.
2010546 - Sialic acid storage diseases. a multiple lysosomal transport defect for acidic monosacc...
18619556 - Degradation of very long chain dicarboxylic polyunsaturated fatty acids in mouse hepato...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  American journal of kidney diseases : the official journal of the National Kidney Foundation     Volume:  37     ISSN:  1523-6838     ISO Abbreviation:  Am. J. Kidney Dis.     Publication Date:  2001 Apr 
Date Detail:
Created Date:  2001-03-29     Completed Date:  2001-05-24     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  8110075     Medline TA:  Am J Kidney Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  758-65     Citation Subset:  IM    
Department of Medicine III, Division of Nephrology and Dialysis, University of Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Double-Blind Method
Drug Administration Schedule
Erythrocytes / chemistry
Folic Acid / administration & dosage,  blood,  therapeutic use*
Homocysteine / blood
Hyperhomocysteinemia / blood,  drug therapy*
Infusions, Intravenous
Leucovorin / administration & dosage,  therapeutic use*
Methylenetetrahydrofolate Reductase (NADPH2)
Middle Aged
Oxidoreductases Acting on CH-NH Group Donors / blood,  genetics
Pyridoxine / blood
Renal Dialysis*
Treatment Outcome
Vitamin B 12 / blood
Reg. No./Substance:
454-28-4/Homocysteine; 58-05-9/Leucovorin; 59-30-3/Folic Acid; 65-23-6/Pyridoxine; 68-19-9/Vitamin B 12; EC 1.5.-/Oxidoreductases Acting on CH-NH Group Donors; EC Reductase (NADPH2)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Melatonin prevents oxidative stress resulting from iron and erythropoietin administration.
Next Document:  Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers.